Group 4C: HR+ Breast Cancer; Biomarkers; Clinical Trials; Targeted Therapies

Thursday, June 15
10:00 am – 11:30 am Eastern Time (US/New York)

Poster #1059:

Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

Poster #1065:

Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

View Poster PDFs

Mentor: Ellen Landsberger, M.D.

Ellen is a retired OBGYN/Maternal Fetal Medicine specialist and since then has pursued her other passion- politics, especially related to women’s health. She has been living with breast cancer for 27 years but did not get involved in advocacy until she was diagnosed with, and treated for metastatic breast cancer (MBC) in 2017. She is a patient advocate at Memorial Sloan Kettering Cancer, the Translational Breast Cancer Research Consortium, and the IMAXT project out of CRUK – Cancer Research of United Kingdom. Ellen is a Project LEAD graduate and enjoys lobbying with the National Breast Cancer Coalition. She recently joined the MBC Alliance as an independent patient advocate and is excited to join GRASP as a patient advocate mentor. Ellen lives in NYC and goes to as many concerts and theater productions as she can!

Twitter: @EllenLands

Scientist: Aileen Fernandez, Ph.D.

Aileen Fernandez’s postdoctoral research is in translational oncology and focuses on identifying and developing biomarkers to better identify which patients with cancer will respond to targeted therapies, improving patient care. Aileen completed her PhD in the Tumor Biology training program at Georgetown University (GU) in 2019. While there, she worked in the laboratory of Dr. Rebecca B. Riggins and focused on triple negative breast cancer, an aggressive breast cancer subtype that disproportionally affects African-American women and lacks targeted therapies. While at GU, Aileen co-founded the Women in Science and Education (WISE) group with her colleagues, serving as the group’s strategist, secretary, and diversity liaison.

Aileen is passionate about leveling accessibility in science and promoting diversity, equity, and inclusion. She also strongly believes in improving science communication to better disseminate information from the scientists’ bench to society.

Twitter: @AileenIlianaPhD